You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

VOCABRIA + REKAMBYS GIVES YOUR PATIENTS TWO MONTHS BETWEEN DOSES AT THE CONTINUATION STAGE OF THEIR TREATMENT1,2

BEFORE TREATMENT INITIATION1,2

  • Ensure patients agree to the required every-2-month dosing schedule and counsel patients about the importance of adherence to scheduled injection visits
  • Set a consistent injection date, the Target Treatment Date, to help keep your patients on track

EVERY-2-MONTH DOSING SCHEDULE1,2

vocabria+rekambys injection schedule

FOLLOWING TREATMENT DISCONTINUATION1,2

  • It is essential to start alternative ARV therapy no later than 2 months after the final injections (or 1 month if after first initiation injections) in order to minimise the risk of developing viral resistance

Optional Oral Lead-In

If you would like to assess tolerability, prescribe 2 tablets (1 cabotegravir and 1 rilpivirine tablet) to be taken once daily with a meal for 1 month (at least 28 days).1,2

EVERY-2-MONTH DOSING WITH WITH ORAL LEAD-IN1,2

vocabria+rekambys injection schedule with oral lead in

When given the choice in SOLAR, more participants and physicians chose to start with injections than via oral lead in3

Manage Missed Injections

  • If a patient plans to miss a scheduled injection visit by >7 days, oral cabotegravir (30 mg tablet) in combination with rilpivirine (25 mg tablet) once daily may be used for up to 2 consecutive months, to replace 1 missed scheduled injection dose of every-2-month VOCABRIA + REKAMBYS1,2
    • The first dose of oral therapy should be taken 2 months (+/- 7 days) after the last injection dose and continued until the day injection dosing is restarted1,2
  • Adherence to scheduled injection visits is important; if a patient missed their Target Treatment Date by >7 days and did not plan for it by taking oral therapy, clinically reassess the patient to determine whether long-acting therapy remains appropriate1,2

How to restart injections after oral bridging or missed injection for patients on every-2-month VOCABRIA + REKAMBYS1,2

oral bridging and missing injections guidance table

Important Drug Interactions1,2,4-6

Vocabria + Rekambys Resources

Explore our supporting materials

Learn More about Patient Preferences

Finding a regimen that your patients prefers

ARV=antiretroviral; CYP3A=cytochrome P450 3A; GI=gastrointestinal; IM=intramuscular;
OAT=organic anion transporter.

References
  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare; 2024. https://www.medicines.ie/medicines/vocabria-600-mg-prolonged-release-suspension-for-injection-35220/spc#tabs
  2. REKAMBYS Summary of Product Characteristics. Janssen-Cilag International NV; 2024. https://www.medicines.ie/medicines/rekambys-35258/spc#tabs
  3. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety and tolerability of switching to long- acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV, 12 month results (SOLAR): A randomised open-label, phase 3b non-inferiority trial. The Lancet HIV. 2023. Published Online 8th August 2023. https:// doi.org/10.1016/S2352-3018(23)00136-4
  4. EDURANT Summary of Product Characteristics. Janssen-Cilag International NV; 2022. https://www.medicines.ie/medicines/edurant-25mg-film-coated-tablets-31961/spc
  5. Antzelevitch C, Sun ZQ, Zhang ZQ, et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol. 1996;28(7):1836-1848. doi: 10.1016/S0735-1097(96)00377-4.
  6. Vieweg WVR, Hancox JC, Hasnain M, et al. Clarithromycin QTc interval prolongation and torsades de pointes: the need to study case reports. Ther Adv Infect Dis. 2013;1(4):121-138. doi:10.1177/2049936113497203.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor.
©2024 GSK group of companies. All rights reserved.

PM-IE-CBR-WCNT-240009 | Date of Preparation: September 2024